Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBVD Hexavalent Vaccine vs Pentavalent + IPV in Healthy Infants
NCT06947499Phase 3Active, not recruiting
- Sponsor
- LG Chem
- Start
- May 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lomustine + bleomycin + vinblastine + doxorubicin in diphtheria, Tetanus, pertussis and 3 more (5 arms), sponsored by LG Chem. Primary endpoints: Seroprotection/seroconversion rate and Geometric mean concentration for pertussis. Started May 2025; status: active, not recruiting.
02
Drugs
lomustine + bleomycin + vinblastine + doxorubicin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT06947499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947499.